EGFR and head and neck squamous cell carcinoma: Clinical studies with the NIR-PIT technique began worldwide in 2015, and the first clinical research (NCT02422979) using the target antibody cetuximab saratolacan (cetuximab conjugated to IR700, or anti-EGFR-IR700 dye conjugate, also known as RM-1929) to target the epidermal growth factor receptor (EGFR) in patients with recurrent head and neck squamous cell carcinoma (rHNSCC) was successfully concluded in 2019, demonstrating the effectiveness and safety of the method and of the product [109].